Pfiz­er cel­e­brates a new FDA ap­proval as the Xalko­ri fran­chise slow­ly winds down

Sales of Pfiz­er’s Xalko­ri may be slip­ping as new drugs squeeze the on­col­o­gy mar­ket, but the phar­ma gi­ant hasn’t lost its ap­petite for new in­di­ca­tions.

The FDA has come through with the most re­cent ap­proval for the drug, giv­ing Pfiz­er a green light to sell the ther­a­py for treat­ment-re­sis­tant cas­es of in­flam­ma­to­ry anaplas­tic lym­phoma ki­nase (ALK)-pos­i­tive my­ofi­brob­las­tic tu­mors. Reg­u­la­tors cite a small but pos­i­tive 21-pa­tient study in pe­di­atric and adult pa­tients:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER